Monopar Therapeutics Inc. Common Stock (MNPR) Stock Price
MNPRStock
$111.89+210.29%52W
Market Cap$751.02M
P/E—
PEG Ratio—
Div yield—
Beta1.42
MNPR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)82.26%
Price vs S&P 500 (4W)-1.32%
VGM Score89.10
MNPR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.65 | -$0.62 | +4.46%(+$0.03) | |
| Q1 2026 | -$0.90 | -$0.46 | +48.75%(+$0.44) | |
| Q4 2025 | -$0.51 | -$0.61 | -19.08%(-$0.10) | |
| Q3 2025 | -$0.40 | -$0.48 | -20.33%(-$0.08) | |
| Q2 2025 | -$0.48 | -$0.35 | +27.59%(+$0.13) |
MNPR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.16
4.16
4.16
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MNPRMonopar Therapeutics Inc. Common Stock | — | — | A | $111.89 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapeutics with a diversified pipeline spanning multiple development stages. The company's programs include Validive for chemoradiotherapy-induced oral mucositis in oropharyngeal cancer, camsirubicin for soft tissue sarcoma, the preclinical antibody MNPR-101 for cancers and severe COVID-19, and the early-stage analog MNPR-202 for multiple cancer types.